| Literature DB >> 22253792 |
Signe Sloth Mogensen1, Lise Aksglaede, Annette Mouritsen, Kaspar Sørensen, Katharina M Main, Peter Gideon, Anders Juul.
Abstract
UNLABELLED: Central precocious puberty may result from organic brain lesions, but is most frequently of idiopathic origin. Clinical or biochemical factors which could predict a pathological brain MRI in girls with CPP have been searched for. With the recent decline in age at pubertal onset among US and European girls, it has been suggested that only girls with CPP below 6 years of age should have brain MRI performed.Entities:
Mesh:
Year: 2012 PMID: 22253792 PMCID: PMC3257249 DOI: 10.1371/journal.pone.0029829
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Anatomical description of 54 brain MRI with abnormal findings.
| Newly diagnosed CNS pathologies | 13 | Known CNS ethiologi | 21 | Incidental findings | 20 |
| Arachnoid cysts | 5 | Chiari II malformations and MMC | 4 | Pineal cysts | 5 |
| Hamartomas | 2 | Hamartoma/glioma and NF1 | 3 | Pituitary microadenomas | 4 |
| Pilocytic astrocytoma | 1 | Astrocytomas | 3 | Pituitary enlargement | 3 |
| Hydrocephalus and corpus callosum agenesia | 1 | Encephalitis sequelae | 2 | Pituitary enlargement | 2 |
| Pineal tumour | 1 | Hydrocephalus | 2 | Asymmetric pituitary | 1 |
| Chiari II malformation | 1 | Meningitis sequelae | 1 | Absent septum pellucidum | 1 |
| Cortical dysplasia in left occipital lobe | 1 | Arachnoid cyst and septo-optic dysplasia | 1 | Variation of perivascular space (normal) | 1 |
| Pontine tumour | 1 | Traumatic CNS injury | 1 | Unspecific white matter lesion | 1 |
| Brainstem tumour | 1 | Hyperintense thalamic lesion | 1 | ||
| Germinoma | 1 | Bone proces (clivus) | 1 | ||
| Porencephalic congenital cyst, hydrocephalus | 1 | ||||
| Insult in left temporoparital region | 1 |
Descriptive characteristics of 13 girls with newly diagnosed brain pathology.
| ID | CPP according to criteria | MRI findings | Age at onset (years) | Age at 1st exam (years) | Pubertal stage | Height (SDS) | Weight (SDS) | BMI (SDS) | BA-CA (years) | Basal FSH (IU/L) | Peak FSH (IU/L) | Basal LH (IU/L) | Peak LH (IU/L) | Peak LH/FSH ratio | E2 (pmol/L) | GnRH agonist therapy | Clinical Outcome |
| 1 | y | Chiari II malformation | 6.2 | 7.9 | B3 | 0,7 | ND | ND | 3,1 | 4,45 | 11,9 | 1,54 | 25,4 | 2.13 | 53 | y | clinical follow up |
| 2 | y | Hypothalamic hamartoma | 6.4 | 11.0 | B4 | 0,9 | 0,8 | 0,9 | 2.5 | 1,6 | ND | 2,34 | ND | ND | 611 | n | MRI follow up |
| 3 | y | Pilocytic astrocytoma | 6.5 | 6.9 | B3 | 1.3 | 0.8 | 0.2 | −1 | 2,31 | 8,94 | 0,15 | 13,3 | 1.48 | 36 | y | Operation |
| 4 | n | Hamartomas (basal ganglia, brain stem, cerebellum), NF type 1 | 7.0 | 7.7 | B1 | 1,1 | 1,3 | 1,1 | 1,3 | 1,73 | 5,62 | 0,06 | 1,56 | 0.28 | 18 | n | clinical follow up |
| 5 | y | Arachnoid cyst | 7.5 | 9.9 | B3 | 1,5 | 2,4 | 1,5 | 3,1 | 2,12 | ND | 1,13 | ND | ND | 227 | n | MRI follow up |
| 6 | y | Pontine tumor | 7.5 | 7.9 | B2 | 1,4 | 1,9 | 1,5 | 2,5 | 1,8 | 5,32 | 0,72 | 10,7 | 2.01 | 30 | y | MRI follow up |
| 7 | y | Hydrocephalus and arachnoid cyst | 7.6 | 8.0 | B2 | 0,7 | 1,6 | 1,3 | −0,1 | 3.77 | 9.47 | 0.89 | 12.5 | 1.32 | 61 | y | MRI follow up |
| 8 | n | Arachnoid cyst | 8.2 | 9.0 | B4 | 1,4 | 4,1 | 2,8 | 2,0 | 4,39 | ND | 3,97 | ND | ND | 47 | y | MRI follow up |
| 9 | n | Hydrocephalus and corpus callosum agenesia | 8.3 | 9.7 | B3 | −2 | 0,1 | 1,6 | 1,3 | 5,79 | 17 | 5,47 | 63,3 | 3.72 | 100 | y | clinical follow up |
| 10 | n | Congenital dysplasia in left occipital lobe | 8.5 | 9.5 | B5 | 0,3 | 0,8 | 1 | 1,5 | 5,43 | 6,77 | 4,4 | 21,3 | 3.15 | 184 | y | MRI follow up |
| 11 | n | Arachnoid cyst | 8.5 | 9.0 | B2 | 2,2 | 1,2 | 0,1 | 1,7 | 8,56 | 14,8 | 1,41 | 28,5 | 1.93 | 62 | y | MRI follow up |
| 12 | n | Arachnoid cyst | 8.5 | 9.1 | B2 | 0,9 | 2,1 | 1,8 | 0,5 | 2,28 | 8,69 | 0,12 | 8,85 | 1.02 | 18 | n | MRI follow up |
| 13 | n | Pineal tumor | 8.5 | 9.5 | B3 | 1,4 | ND | ND | 0.5 | 5,03 | ND | 1,18 | ND | ND | 160 | y | MRI follow up |
y: yes, n:no, ND: Not Determined,
*: indicated but parental decline.
Figure 1Brain MRI of newly diagnosed pathology.
Pathological brain MRI scans from 6 representative girls with precocious puberty and no other CNS symptoms. ID indicating their identification number (see Table 2).
Figure 2Brain MRI scans of girls with incidental findings.
Typical incidental MRI findings in the CNS from three representative girls with early or precocious puberty.
Comparison of clinical and biochemical characteristics girls according to their brain MRI findings.
| I Non-pathological | II CNS Pathology | IIb vs Ia | II vs I | IIb vs I | |||
| Ia Normal MRI | Ib Incidental CNS abnormalities | IIa Known CNS abnormalities | IIb Newly diagnosed CNS Pathologies | p-value | p-value | p-value | |
|
| 175 | 20 | 21 | 13 | |||
|
| 7,7 (0,4 to 9,1) | 7.5 (1.0 to 9.5) | 7,7 (2,5 to 10,0) | 7,6 (6.2 to 8,5) | 0.785 | 0.808 | 0.715 |
|
| 8,5 (1,5 to 10,9) | 8,5 (1,0 to 10,7) | 8,5 (3,3 to 10,6) | 9,0 (6.9 to 11,0) | 0.196 | 0.819 | 0.187 |
|
| 1,7 (−1,8 to 4,3) | 1,4 (−,5 to 2,9) | 0,8 (−1,4 to 6,1) | 1,5 (−1,0 to 3,1) | 0.861 | 0.347 | 0.933 |
|
| 1,0 (−3,2 to 4,8) | 0,6(−1,7 to 2,9) | 0,1 (−2,1 to 2,8) | 1,1 (−1,7 to 2,2) | 0.938 |
| 0.952 |
|
| 1,0 (−2,7 to 4,9) | 1.0 (−1,9 to 2,7) | 1,1 (−0,4 to 3,5) | 1,3 (0.1 to 2,8) | 0.408 | 0.635 | 0.421 |
|
| 42 (18 to 427) | 37 (18 to 1052) | 40 (18 to 401) | 53 (18 to 611) | 0.198 | 0.518 | 0.203 |
|
| 0,3 (0,05 to 9,4) | 0,1 (0,05 to 15,3) | 0,8 (0,05 to 6,7) | 1,2 (0,06 to 5,5) |
|
|
|
|
| 7,5 (0,2 to 77.9) | 5,6 (1,7 to 21.1) | 12,7 (1,0 to 50,1) | 13.3 (1,6 to 63,3) | 0.084 |
| 0.068 |
|
| 1,0 (0,1 to 9,8) | 0,7 (0,2 to 2.1) | 1,5 (0,1 to 6,8) | 1,9 (0,3 to 3,72) | 0.082 | 0.086 | 0.066 |
BA-CA: Bone age - Chronological age.
Summary of studies of precocious puberty.
| Study | Year | Total | all patologies | Hamartomas | Astrocytomas/Gliomas | Arachnoid cysts | Other | Incidental findings | Organic precocpis puberty (%) |
| Bridges et al. | 1994 | 91 | 6 | 1 | 1 | 4 | 7 | ||
| Chalumeau et al. (pilot) | 2002 | 197 | 11 | 6 | 3 | 1 | 1 | 6 | |
| Chalumeau et al. (validation) | 2002 | 42 | 3 | 3 | 7 | ||||
| Chalumeau et al. | 2003 | 443 | 35 | 23 | 7 | 2 | 3 | 9 | 8 |
| Chematily et al. | 2001 | 230 | 11 | 6 | 3 | 1 | 1 | 5 | |
| Choi et al. | 2007 | 45 | 11 | 5 | 4 | 2 | 24 | ||
| Cisternino et al. | 2000 | 428 | 17 | 7 | 4 | 3 | 3 | 9 | 4 |
| Kornreich et al. | 1995 | 51 | 11 | 4 | 1 | 6 | 22 | ||
| Ng et al. | 2003 | 67 | 9 | 6 | 1 | 1 | 1 | 13 | |
| Soriano-Guilén et al. | 2010 | 226 | 23 | 11 | 12 | 10 | |||
| Taher et al. | 2004 | 43 | 4 | 2 | 1 | 1 | 2 | 9 | |
| Mogensen et al. | 2011 | 208 | 13 | 2 | 1 | 5 | 5 | 20 | 6 |
| Studies of girls with known pathologies | |||||||||
| Rivarola et al. | 2001 | 12 | 12 | 4 | 3 | 4 | 1 | ||
| Trivin et al. | 2006 | 15 | 15 | 10 | 3 | 1 | 1 | ||
| Trivin et al. | 2006 | 52 | 52 | 20 | 5 | 27 | |||
| Mogensen et al. | 2011 | 21 | 21 | 3 | 3 | 1 | 14 |
*Previously diagnosed,
only newly diagnosed.